Immix up on pediatric patient enrollment approval in cancer therapy trial

Immix Biopharma

11/11/2022 16:12

** Shares of cancer drug developer Immix Biopharma Inc
 IMMX.O  rise 13.3% to 85 cents
    ** Co says it received approval of Institutional Review
Board (IRB) to enroll pediatric patients for upcoming IMX-110
clinical trial
    ** Co is pursuing U.S. FDA approval for IMX-110 to treat
rhabdomyosarcoma, and soft tissue sarcoma
    ** Soft tissue sarcoma is cancer that develops in soft
tissues such as fat, muscle, nerves and can be found in any part
of the body
    ** U.S. FDA in early January granted IMX-110 rare pediatric
disease designation for rhabdomyosarcoma, a life-threatening
form of cancer in children 
    ** Enrolling pediatric patients in a clinical trial is a key
requirement for FDA approval of a Priority Review Voucher (PRV) 
    ** PRV holders can benefit from an expedited six-month
review of a new drug application for any disease by the FDA  
    ** PRV's are also transferable to other co's and have
historically sold for as much as $67 to $350 mln, according to a
2020 government report on drug development
    ** Including session's gain, stock down ~76% YTD
 (Reporting by Pratik Jain)
 ((Pratik.Jain@thomsonreuters.com;))